Condition: Non Small Cell Lung Cancer · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced adult non-small cell lung cancer (NSCLC).
This description comes directly from the study's public registry record.
Zhenfeng Zhang, MD, PhD · 0086-020-39195966 · zhangzhf@gzhmu.edu.cn
Bingjia He, MD · 14748877800
Always discuss trial participation with your own doctor first.
| Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05060796